BrW, brain weight (g); CL, clearance (mL/min/kg); clogP, calculated logarithm of the octanolwater partition coefficient; CMR, calculated molar refractivity (mL/mol); HBA, number of hydrogen bond acceptors; HBD, number of hydrogen bond donors; LBF, liver blood flow; MAE, mean absolute error; MLP, maximum life span potential (yr); MRT, mean residence time (minutes); MW, molecular weight; nrot, number of rotatable bonds; PSA, polar surface area 
DMD #6619
The use of in vivo preclinical pharmacokinetic data generated during lead optimization to predict human pharmacokinetic properties is commonplace in the pharmaceutical industry, with a variety of methodologies available for data predictivity (Pogessi, 2004; Ings, 1990) . Recent investigations using a diverse set of 103 non-peptide xenobiotics with rat, dog, monkey, and human intravenous pharmacokinetic data have yielded a number of interesting and useful observations, including the value of monkey pharmacokinetic data in successful prediction of human pharmacokinetics, and the relative lack of added value provided by dog pharmacokinetic data (Ward and Smith, 2004a; Ward and Smith, 2004b). Additionally, when several quantitative methodologies including liver blood flow-based scaling and body weight-based allometry were applied to this dataset for predicting human clearance (CL), the greatest accuracy was achieved using the monkey liver blood flow approach, rather than allometry, even with the inclusion of mechanistic or empirical allometric correction factors (Nagilla and Ward, 2004). Finally, the availability of this comprehensive dataset has allowed the identification of a set of associations between preclinical pharmacokinetic properties, two-dimensional molecular features, and extrapolative success or failure of human pharmacokinetics (Jolivette and Ward, 2005) . These calculated physiochemical properties can then be used to predict the extrapolative success or failure of rat, dog, and monkey data to project human pharmacokinetic parameters.
Despite the clear utility of this extrapolation dataset, one of the concerns about the various relationships expounded to date has been the applicability of these observations beyond the chemical space originally circumscribed. Largely, the lack of additional molecules for which a complete set of clinical and preclinical data are available in the literature has hindered further exploration in this area; non-human primate literature data are particularly sparse. In the present This article has not been copyedited and formatted. The final version may differ from this version. investigation, the dataset is extended by an additional 21 compounds; 8 compounds for which rat, dog, monkey, and human data have already been published, and 13 compounds for which non-rodent preclinical data were not previously available and for which either monkey or dog data were generated de novo for this study. This dataset was of particular interest since it was enriched with molecules likely to be encountered in a modern drug discovery setting (Lipinski, features, a criteria largely unmet in the previous dataset. Interestingly, as a whole, compounds included in this dataset were biased towards higher CL compounds across all species than those found in the previous dataset. Using this dataset, human CL, distributional volume at steady state (Vd), and mean resident time (MRT) were predicted from each preclinical species alone using the liver blood flow technique, as well as allometric scaling either with or without application of empirical correction factors ( Figure 1) . Additionally, the applicability of the previously developed molecular feature associations with rat, dog, and monkey predictivity of human pharmacokinetics was examined.
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METHODS
Literature Data Collection. Details underlying the collection of this data set were identical to those detailed elsewhere (Ward and Smith, 2004a) . Eight molecules, [3-{2-oxo-3-[3-(5,6,7,8- tetrahydro- [1, 8] naphthyridin-2-yl)propyl-imidazolidin-1-yl}-3(S)-(6-methoxy-pyridin-3-yl)propionic acid ("α V β 3 antagonist"), epiroprim, flindokalner, garenoxacin, midazolam, ofloxacin, PNU-96391, and semaxanib] were identified with complete intravenous pharmacokinetic data in rat, dog, monkey, and human. Literature data were found for 11 additional xenobiotics (amiodarone, biperiden, chlorpromazine, diltiazem, felodipine, methadone, nifedipine, propafenone, remoxipride, verapamil, and vinorelbine) in rat, dog, and human; but for which no data were reported for monkey. Likewise, 2 additional molecules (haloperidol and mifepristone) possessed published intravenous pharmacokinetic data in rat, monkey, and human, but for which no data were reported for dog. 
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Finally, the role of two-dimensional molecular properties in predicting extrapolative success or failure of each preclinical species was also determined both qualitatively and quantitatively through the application of the molecular property associations described for properties which provided statistically significant differentiation between extrapolative success and failure and assignment of molecular property associations which provided this discrimination. For instance, the associations state that for molecules with a clogP > 0, extrapolation based on rat data would result in a human CL prediction that would be a quantitative outlier (corrected for LBF differences between the species, the predicted human CL from rat would not be within 2-fold of the observed human CL value). Next, "data-dependent" associations were applied, in which preclinical predictivity was interrogated as a function of both molecular features and the experimentally determined pharmacokinetic parameters in a given preclinical species. This second approach utilized an additional descriptor, based on CL categories, which was also considered with the calculated molecular properties to determine parameters which provided differentiation between extrapolative inliers and outliers. For example, the molecular associations predict that for compounds with low CL in the dog and PSA > 160 Å 2 , the resulting human CL prediction would be a quantitative outlier with respect to the dog CL (corrected for LBF differences between the species, the predicted human CL from dog would not be within 2-fold of the observed human CL value). quantitative assessment, when predicted human Vd was within 2-fold of the experimentally determined value, the prediction was considered an extrapolative inlier, and outside 2-fold, the prediction was considered an extrapolative outlier; MAE was also determined as described earlier. Human Vd was also predicted from three-species allometric scaling, with the same qualitative and quantitative inlier criteria applied. Finally, the role of two-dimensional molecular properties in the extrapolative success or failure was also determined both qualitatively and quantitatively through the application of molecular property associations as described previously quantitative assessment, a correct prediction was declared when the predicted human MRT was within 2-fold of the experimentally determined value. Lastly, MAE and %MAE were also determined for each predictive method as described previously.
Volume of Distribution Data
This article has not been copyedited and formatted. The final version may differ from this version. For each molecule, the methods that afforded the quantitatively most and least accurate predictions in terms of absolute error in each prediction were tallied ( Figure 3) . In terms of the number of occurrences rat and dog yielded the most accurate predictions the least often, where human CL was most accurately predicted for only 4 of the 21 compounds by each of these species. The dog most often yielded the worst prediction of human CL, where the error was the greatest from this species for 10 of the 21 compounds. Monkey LBF and exponent rulecorrected allometry were the most accurate prediction methods the most often; these approaches yielded the most accurate predictions for 6 and 7 of the 21 compounds, respectively. Predictions from exponent rule-corrected allometry was slightly better than monkey LBF scaling in this regard with one more correct prediction, however, in terms of predictivity for all predictive techniques, both methodologies yielded equivalent MAE, at 6.08 mL/min/kg.
Molecular property associations (Jolivette and Ward, 2005) were next applied to the CL dataset (Table 3) . Overall, application of these molecular feature criteria resulted in improved predictivity for each preclinical species, as well as adding the ability to discern when a prediction would likely be incorrect. As an example, using the results for data-independent quantitative predictions of human CL from dog as an example ( from monkey demonstrated a slight increase in overall error. Application of the dataindependent associations in a quantitative manner was more useful, where the molecular property associations were used to make predictions for each compound; based on the molecular property associations there was never an instance where a "no prediction" result was generated based on these associations. Again, when an inlier was predicted, MAE was lower for molecules than for the entire dataset; furthermore, MAE for predicted outliers was indeed higher than for the entire dataset. These trends were brought out even further when the data-dependent associations were applied (Table 4) . In all instances, application of these associations resulted in lower MAE values for predicted inliers and higher MAE values for predicted outliers (Figure 4 ).
For instance, predictions for data-dependent qualitative predictions of human CL from rat (Table   4 , row 1) based on the associations 15 extrapolative predictions were made and 6 compounds were not predicted; 3 compounds were predicted to be extrapolative inliers (same CL category between rat and human) while 12 compounds were predicted to be extrapolative outliers (different CL category between rat and human). Of these 15 predictions, 12 were correctly predicted (80.0%); 2 of the 3 compounds predicted to be an extrapolative inliers were correctly predicted (66.7%) with an MAE of 3.14 mL/min/kg, while 10 of the 12 compounds predicted to This be an extrapolative outlier were correctly predicted (83.3%) with an MAE of 10.91 mL/min/kg.
Furthermore, the overall predictivity of rat and dog increased substantially with the application of these molecular feature associations compared to LBF scaling alone. Rat LBF scaling to predict human CL was correct 33% and 52% for qualitative and quantitative predictions, respectively, while both qualitative accuracies increased to ~80% after application of the molecular feature associations and no improvement was noted in the quantitative predictions.
However, only slight increases in predictive accuracy were noted for monkey after application of the associations.
Human Distributional Volume Predictions. Examination of the intrinsic relationship between
human Vd and the preclinical species revealed that both rat and dog had a tendency to overestimate human Vd with 8 and 9 of the 21 compounds falling above the + 0.7 L/kg line, respectively; monkey was less biased with only 5 of the compounds above this line (Figure 4 ).
The preclinical Vd values for all 21 compounds were compared both qualitatively and quantitatively to human Vd and predicted using allometry (Table 5 ). On the basis of the number of compounds correct qualitative predictions, dog appeared to be the most predictive followed by the other predictive methodologies. When compared quantitatively, there were no substantial differences between rat, dog, and monkey. The ability of allometric scaling to predict human Vd was quantitatively similar to the preclinical species, while allometry exhibited a slightly higher MAE than any of the preclinical species alone. Although the rat had the lowest incidence of successful qualitative predictions and comparable quantitative predictions compared to the other preclinical species, the overall MAE associated with predictions from the rat were the lowest, This article has not been copyedited and formatted. The final version may differ from this version. disappointing when assembled by Vd class qualitatively, with no substantial improvement in predictivity for dog and monkey, and a decrease in predictivity for rat (Table 6 ).
Additionally, the MAE between predicted inliers and outliers are not discriminated appropriately from the overall dataset regardless of species or prediction methodology.
Similarly, the number of correct quantitative predictions from rat and dog also decreased compared to the other prediction methodologies described above, although the MAE for the predicted outliers being increased compared to the entire dataset. However, a substantial improvement in percent correct was noted for quantitative predictions from monkey where nearly 90% of the predictions were correct and the MAE for the predicted inliers being decreased compared to the entire dataset.
Human Mean Residence Time Predictions. Prediction of human MRT was qualitatively most
accurate from monkey predictive approaches, while quantitatively, predictions were similar across all three preclinical species, with dog slightly more predictive (Table 7) . Qualitatively This article has not been copyedited and formatted. The final version may differ from this version. From these analyses have arisen some intriguing conclusions, including the general utility of nonhuman primate data in lead optimization, the superiority of CL scaling from monkey data alone compared to allometric scaling, and the ability to apply "rules" based on two-dimensional molecular features to assess human predictivity from preclinical data. However, although the aforementioned dataset is the largest such species-comprehensive dataset compiled to date, the size of the dataset was particularly limited by data availability (particularly monkey data).
Furthermore, although quite diverse, the original dataset was weighted somewhat towards lower molecular weight, less lipophilic molecules; average molecular weight and clogP values were Likewise, human Vd was similarly well-predicted from any of the preclinical species, and allometry also provided comparable Vd predictivity. Finally and most importantly, the value of both the data-independent and data-dependent molecular associations for assigning preclinical predictivity was confirmed, especially for CL. Given the dataset concerns described above, the successful application of these findings to the present data are particularly encouraging. These observations lend further support to the continued use of non-human primates in Despite the clear successes of this test set exercise, not all of the observations from the previous dataset applied here. First, while LBF scaling from rat and dog to human CL resulted in similar predictivity as in the original dataset, predictivity from monkey LBF scaling was somewhat lower in this dataset (~48%) compared to the original dataset (68%). However, similar to the findings in the previous exercise, the error associated with the predictivity, in terms of MAE, was smallest from monkey LBF scaling when compared to that of the other preclinical species and equal to exponent rule corrected allometry predictions. Although this decreased predictivity in the monkey was somewhat offset in the overall MAE as well as by the application of the molecular features analysis, it is interesting that these putatively more 'discovery-like' molecules demonstrated more difficulty in extrapolating to human pharmacokinetics, and may suggest increased caution in future human predictions with these types of molecules.
Additionally, not all of the previously-identified molecular associations applied as well to the present dataset. In particular, the monkey qualitative CL predictions and all of the quantitative volume predictions were not as useful as hoped; this could be due in part to some of the 'borderline' molecule categorizations, specifically Vd classifications of methadone and remoxipride which were borderline in multiple species. The importance in monkey data for prediction of human MRT was confirmed from the previous analysis.
Regardless of these limitations, the impact of the successful application of the molecular In summary, the findings in this investigation support the application of previous studies to molecules with more 'discovery-like' molecular features, particularly with respect to the use of non-human primate data in pharmacokinetic screening and the application of two-dimensional molecular features analysis to improve preclinical predictivity of human pharmacokinetics, particularly the data-dependent associations. The relationships derived for this 21-compound dataset should be considered preliminary as differences between the two compound datasets were already noted; further refinement to these approaches may be necessary as more compounds can be included in the analysis. These observations also support the value of alternative approaches to allometric scaling in predicting human CL, Vd and MRT, where comparable predictive power was noted from monkey alone, and in some cases, superior predictivity of human PK was observed. The ability to accurately estimate human PK in fewer preclinical species certainly represents an attractive resource savings; compounds can be selected to progress into selected species based on their molecular features and predicted PK, e.g., conducting PK studies in the rat and not in the monkey for compounds with molecular properties associated with successful extrapolation of human CL from rat data and unsuccessful extrapolation from monkey data, thereby resulting in fewer in vivo PK studies. Finally, the predictive power of combining in silico and in vivo approaches is exemplified. Future investigations in this laboratory will continue to focus in the integration of diverse data to form a comprehensive human pharmacokinetic prediction paradigm, particularly the use of in vitro plasma protein binding and metabolic stability data.
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1. three-species allometry 2. three-species allometry corrected for the rule of exponents 3. scaling from rat, dog, and monkey 4. application of data-independent molecular property associations 5. application of data-dependent molecular property associations generated monkey PK for 11 compounds generated dog PK for 2 compounds 21 compound dataset with rat, dog, monkey, and human PK outcomes for each method:
• qualitative (class) predictivity • quantitative (within 2-fold) predictivity
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